-+ 0.00%
-+ 0.00%
-+ 0.00%

ESTRELLA IMMUNOPHARMA ANNOUNCES FIRST PATIENT DOSED IN DOSE-EXPANSION PHASE OF STARLIGHT-1 TRIAL AND REPORTS DURABLE RESPONSE RATE IN ADVANCED B-CELL NON-HODGKIN’S LYMPHOMA

Reuters·07/24/2026 12:00:00

Please log in to view news